A rationally designed peptide enhances homologous recombination in vitro and resistance to DNA damaging agents in vivo.
Chen
Li-Tzu
LT
Institute of Biochemical Sciences, National Taiwan University, Taipei 106, Taiwan.
Wang
Andrew H-J
AH
D000255:Adenosine Triphosphate / Q000378:metabolism; D000595:Amino Acid Sequence; D045744:Cell Line, Tumor; D002945:Cisplatin / Q000633:toxicity; D004249:DNA Damage / Q000187:drug effects*; D004277:DNA, Single-Stranded / Q000737:chemistry; D004317:Doxorubicin / Q000633:toxicity; D029968:Escherichia coli Proteins / Q000737:chemistry / Q000378:metabolism; D006801:Humans; D008969:Molecular Sequence Data; D009842:Oligopeptides / Q000737:chemistry / Q000494:pharmacology*; D010455:Peptides / Q000737:chemistry / Q000494:pharmacology*; D011938:Rec A Recombinases / Q000737:chemistry* / Q000378:metabolism; D011995:Recombination, Genetic / Q000187:drug effects*
D004277:DNA, Single-Stranded; D029968:Escherichia coli Proteins; D009842:Oligopeptides; D010455:Peptides; C551591:isoleucyl-arginyl-phenylalanyl-leucyl-threonyl-alanyl-arginyl-arginyl-arginine; D004317:Doxorubicin; D000255:Adenosine Triphosphate; D011938:Rec A Recombinases; D002945:Cisplatin